Delivery Order SPE2DB20D3303-SPE2DB25FA3ND
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,817.34 on August 19, 2025, for the supply of Fluticasone Propionate HFA 110 mcg inhalers (12 grams). This contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on August 20, 2025, for Fluticasone Propionate HFA 110 MCG inhalers (12 GM) with a ceiling value of $1,004.06. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 21, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA. The place of performance is listed as the contractor's corporate office...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a $2,532.00 delivery order to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 220 mcg inhalers (12 grams). This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a standard pharmaceutical procurement under the company's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Fluticasone Propionate HFA 220 micrograms in 12-gram inhalers, with a ceiling value of $3,278.52. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 13, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement for...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Fluticasone Propionate HFA 220 micrograms in 12-gram inhalers, valued at $1,725.32. This firm fixed-price delivery order, which is not set-aside and therefore awarded through open competition, has an ultimate completion date of September 10, 2025. The award represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing...
- The Defense Logistics Agency's Medical Supply Chain awarded a $2,875.14 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Fluticasone Propionate HFA 220 mcg inhalers (12 grams). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Fluticasone Propionate HFA 44 mcg 10.6gm inhalers, valued at $1,257.22. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This is a firm fixed-price, non-set-aside contract with a ceiling value of $1,051.91 and an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,108.90 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Fluticasone Propionate HFA 110 mcg inhalers (12 grams), with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Fluticasone Propionate HFA 44 micrograms in 10.6-gram inhalers, with a ceiling value of $4,633.71. This competitive award, utilizing firm fixed pricing, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The order is set to be completed by...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3NDDelivery Order
AmerisourceBergen Drug Corp was awarded a $3,941.38 delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Fluticasone Propionate HFA 220 mcg inhalers (12 grams). The contract is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively procured. This delivery order is a child contract issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military healthcare systems and other federal healthcare agencies. The delivery order for this respiratory medication aligns with the company's established role as a pharmaceutical prime vendor supporting Defense Health Agency requirements and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 9/10/25 |